Clinical trials: Drug Metabolism
Spinal Cord Injury, Bone Loss
Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide
The purpose of this study is to determine if a year of alendronate treatment will maintain or increase bone mass density (BMD) compared to baseline BMD values in people with chronic spinal cord injury (SCI).
- Conditions
- Spinal Cord Injury, Bone Loss, Osteoporosis
- Trial name
- NCT02195895
- Testing
- Alendronate, Calcium, Vitamin D
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Diabetes Mellitus, Cigarette Smoking
The Effectiveness of Smoking Cessation in Prediabetic Smokers
Existing literature investigating the impact of smoking cessation on new-onset diabetes mellitus (DM) risk is conflicting. Combing the need for smoking cessation and body weight self-management to prevent the progression of…
- Conditions
- Diabetes Mellitus, Cigarette Smoking, Prediabetes
- Trial name
- NCT01926041
- Testing
- Varenicline for tobacco smoking cessation, Individualized counseling about both smoking cessation and weight control techniques
- Where
- Taiwan
- Volunteers
- 589 people
- Sponsor
- National Taiwan University Hospital
Cardiovascular Disease (CVD), Hypertension
Veteran Peer Coaches Optimizing and Advancing Cardiac Health
The purpose of this study is to test if having a Veteran peer health coach will improve blood pressure control among Veterans with high blood pressure and at least one other Cardiovascular disease (CVD) risk factor.
- Conditions
- Cardiovascular Disease (CVD), Hypertension, Hyperlipemia, Obesity
- Trial name
- Vet-COACH (NCT02697422)
- Testing
- Community-based peer health coach intervention
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan
The purpose of this study was evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an Sulfonylurea taken QD or twice daily (BID) in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01318083
- Testing
- Alogliptin and glimepiride, Glimepiride
- Volunteers
- 312 people
- Sponsor
- Takeda
Peripheral Arterial Disease
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral arterial disease (PAD) occurs when arteries become narrowed or hardened because of a build-up of plaque or fat deposits.
- Trial name
- NCT00687076
- Testing
- Ezetimibe, Niaspan, Statin therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Baylor College of Medicine
Drug-Interactions
Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
This study will evaluate drug-drug interactions between cannabis extracts containing Tetrahydrocannabinol (THC) and THC+ Cannabinoids (CBD) and probe drugs for select CYP450 pathways including: caffeine (CYP1A2), omeprazole…
- Trial name
- NCT04201197
- Testing
- Inje cocktail, THC Cannabis extract, THC/CBD Cannabis Extract
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Osteoporosis
FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of FOSAMAX PLUS / FOSAMAX PLUS…
- Trial name
- NCT01065779
- Testing
- FOSAMAX PLUS, FOSAMAX PLUS D
- Volunteers
- 880 people
- Sponsor
- Organon and Co
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent…
- Trial name
- NCT01697592
- Testing
- Omarigliptin
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Medication Adherence, Medication Compliance
Connected Healthcare for Individuals Living at Home With Chronic Conditions
Managing and taking medications as prescribed can be a difficult task. This is especially true for older adults living at home with chronic conditions while managing multiple prescribed medications.
- Conditions
- Medication Adherence, Medication Compliance, Medication Nonadherence, Hypertension
- Trial name
- NCT04339296
- Testing
- Spencer
- Where
- Canada
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Alberta Health Services, Calgary
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Sepsis, Kidney Injury
Thiamine as a Renal Protective Agent in Septic Shock
This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on renal function in septic shock.
- Conditions
- Sepsis, Kidney Injury, Thiamine Deficiency
- Trial name
- NCT03550794
- Testing
- Thiamine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- Beth Israel Deaconess Medical Center
Type 2 Diabetes Mellitus
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin…
- Trial name
- NCT01065766
- Testing
- Sitagliptin/metformin
- Volunteers
- 4,065 people
- Sponsor
- Merck Sharp & Dohme LLC
Fabry Disease
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
The objective was to determine the effects of a single dose of migalastat hydrochloride (HCl) (migalastat) 150 and 450 milligrams (mg) on the safety and plasma pharmacokinetics (PK) of agalsidase and the effects of agalsidase on…
- Trial name
- NCT01196871
- Testing
- Migalastat HCl, Agalsidase Beta, Agalsidase Alfa
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 20 people
- Sponsor
- Amicus Therapeutics
Diabetes Mellitus, Type 2
Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes
This study evaluates a mobile phone-delivered intervention, called REACH (Rapid Education/Encouragement And Communications for Health), in supporting adults with type 2 diabetes in their self-management relative to a control…
- Trial name
- NCT02409329
- Testing
- REACH, Helpline and A1c results, REACH + FAMS
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform…
- Trial name
- ON TARGET DM (NCT05073692)
- Testing
- SU, DPP4, SGLT2i
- Where
- 6 sites in United States
- Volunteers
- 241,981 people
- Sponsor
- Kaiser Permanente
Diabetes Mellitus, Type 2
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US)…
- Trial name
- NCT02750930
- Testing
- Albiglutide, Auto-injector
- Where
- 27 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Comprehensive Add on Study in Japan
The objective of the current study is to investigate the safety and efficacy of linagliptin (5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes mellitus and insufficient glycaemic control…
- Trial name
- NCT01204294
- Testing
- Linagliptin, Metformin
- Where
- 43 sites in Japan
- Volunteers
- 574 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
A multiple dose study to assess the safety and pharmacokinetics of an investigational drug in patients with type 2 diabetes. The primary hypotheses of the study are that multiple daily MK-0941 in subjects with T2DM with or…
- Trial name
- NCT00511667
- Testing
- MK0941
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Congenital Adrenal Hyperplasia (CAH)
Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
This study was developed to determine if a combination of four drugs (flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone) can normalize growth in children with congenital adrenal hyperplasia.
- Trial name
- NCT00001521
- Testing
- Fludrocortisone, Hydrocortisone, Letrozole
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of night time low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 2 (NCT01435616)
- Testing
- Glargine, LY2605541
- Where
- 167 sites in United States, Argentina and 21 more
- Volunteers
- 1,538 people
- Sponsor
- Eli Lilly and Company